|Bid||0.00 x 1100|
|Ask||0.00 x 900|
|Day's Range||75.35 - 80.74|
|52 Week Range||16.12 - 105.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.41|
The ongoing race to make vaccines and therapies for the coronavirus has led to a tremendous amount of speculation in the market. For others, like Sorrento Therapeutics (NASDAQ: SRNE) and BioNTech (NASDAQ: BNTX), working on coronavirus products has created massively inflated prices that are vulnerable to melting down during a market crash. Both stocks have grown more than 130% this year, but neither company has sales revenue from the successful commercialization of any pipeline project.
For a while, the U.S. late-stage clinical trials of coronavirus vaccine candidates developed by AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ) were in limbo. On Friday, AstraZeneca announced that the U.S. Food and Drug Administration authorized the resumption of the late-stage study for coronavirus vaccine candidate AZD1222. The same day, J&J announced that it also was preparing to resume the U.S. late-stage study of its experimental COVID-19 vaccine, JNJ-78436735.
Moderna and Novavax announced advances for their respective Covid-19 vaccine candidates, with the U.K. starting a 'rolling review' of Moderna's vaccine and Novavax expanding its key trials.